Overview

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Status:
Completed
Trial end date:
2018-10-08
Target enrollment:
Participant gender:
Summary
The study will determine the maximum tolerated dose and thus the recommended phase II dose and schedule of the compound and characterize the safety.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Infigratinib